These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases. Marsk A; Grunewald C; Saltvedt S; Valentin L; Almström H Acta Obstet Gynecol Scand; 2006; 85(5):534-8. PubMed ID: 16752230 [TBL] [Abstract][Full Text] [Related]
10. Effect of routine screening for Down's syndrome on the significance of isolated fetal hydronephrosis. Thompson MO; Thilaganathan B Br J Obstet Gynaecol; 1998 Aug; 105(8):860-4. PubMed ID: 9746378 [TBL] [Abstract][Full Text] [Related]
11. Down's syndrome screening with nuchal translucency at 12(+0)-14(+0) weeks and maternal serum markers at 14(+1)-17(+0) weeks: a prospective study. Rozenberg P; Malagrida L; Cuckle H; Durand-Zaleski I; Nisand I; Audibert F; Benattar C; Tribalat S; Cartron M; Lemarié P; Stoessel J; Capolagui P; Jansé-Marec J; Barbier D; Allouch C; Perdu M; Roberto A; Lahna Z; Giudicelli Y; Ville Y Hum Reprod; 2002 Apr; 17(4):1093-8. PubMed ID: 11925411 [TBL] [Abstract][Full Text] [Related]
12. Prenatal screening for Down's syndrome with use of maternal serum markers. Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344 [TBL] [Abstract][Full Text] [Related]
13. Influence of ethnic origin on nuchal translucency screening for Down's syndrome. Thilaganathan B; Khare M; Williams B; Wathen NC Ultrasound Obstet Gynecol; 1998 Aug; 12(2):112-4. PubMed ID: 9744055 [TBL] [Abstract][Full Text] [Related]
14. Screening for Down's syndrome in the first trimester: combined risk calculation, methodology, and validation of a web-based system. Kublickas M; Crossley J; Aitken D Acta Obstet Gynecol Scand; 2009; 88(6):635-8, 7p following 638. PubMed ID: 19330568 [TBL] [Abstract][Full Text] [Related]
15. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening. Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311 [TBL] [Abstract][Full Text] [Related]
16. [First trimester ultrasound screening for nuchal translucency as marker of Down's syndrome]. Herman A; Maymon R; Dreazen E; Bukovsky I; Weinraub Z Harefuah; 1997 Jan; 132(2):94-100. PubMed ID: 9119309 [No Abstract] [Full Text] [Related]
17. Prenatal screening for fetal aneuploidy in singleton pregnancies. Chitayat D; Langlois S; Douglas Wilson R; ; J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752 [TBL] [Abstract][Full Text] [Related]
18. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study. Audibert F; Dommergues M; Benattar C; Taieb J; Thalabard JC; Frydman R Ultrasound Obstet Gynecol; 2001 Jul; 18(1):26-31. PubMed ID: 11489221 [TBL] [Abstract][Full Text] [Related]
19. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399 [TBL] [Abstract][Full Text] [Related]
20. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Wald NJ; Hackshaw AK Prenat Diagn; 1997 Sep; 17(9):821-9. PubMed ID: 9316126 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]